Navigation Links
Novavax Announces Manufacturing Management Appointments
Date:6/14/2010

ainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, among other things, the following: our ability to progress any product candidates into pre-clinical studies or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; clinical trial results; even with positive data from pre-clinical studies or clinical trials, the product candidate may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the United States and, to date, no governmental authority has approved any of our vaccine candidates for sale; influenza is seasonal in nature, and if approval or commercial launch after approval is not timely in relation to the influenza season, we may not be able to manufacture or sell our influenza vaccines on terms favorable to us until the next influenza season, if at all; we have not manufactured any of our vaccine candidates at a commercial level; we utilize a unique manufacturing process and the scale-up of that process may prove difficult and/or costly; our dependence on third parties to manufacture and distribute our vaccines; risks associated with conducting business outside of the United States; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equi
'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Movement for Indefinite Life Extension (MILE) ... technologies and awareness. The event is taking place from ... 21st 2015, in a live Google Hangout broadcast from ... of MILE, says, “Our lives are in our hands, ... Indefinite Life Extension is raising awareness about bio-sciences and ...
(Date:2/26/2015)... , Feb. 26, 2015 BioEnterprise today announced ... have attracted more than $2 billion in growth funding ... and national investors, strategic sources, state – including the ... of the $2 billion has been raised in the ... on the heels of the BioEnterprise Midwest Healthcare ...
(Date:2/26/2015)... Frederick, MD (PRWEB) February 26, 2015 ... solutions provider, released FreezerPro® version 6.2 – the latest ... The FreezerPro® reputation is that of a quick and ... related work. With the latest version, RURO engineering has ... on import to move large amounts of sample records. ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015 ... Gold Partner status in Oracle PartnerNetwork. In attaining Gold ... its commitment to establish Oracle-related knowledge in delivering Ceres, ... challenges of joint customers. Originally developed for ... to rapidly zoom in and out of massive amounts ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4RURO Releases FreezerPro® version 6.2 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... physicists have successfully landed a one-two punch on a ... then dosing its perimeter with a laser beam, to ... standstill. The findings, published in Nature Physics ... special quantum properties and in precision-measurements for nanotechnology. The ...
... N.C., June 17 Pharmaceutical Institute (PI), a leading provider ... today announced the release of a new e-course titled, ... newest addition to the company,s Managed Markets Excellence(TM) ... e-course provides a comprehensive overview of the challenges confronting the ...
... (NYSE: DGX ), the world,s leading provider of ... for its previously announced cash tender offer to purchase up ... of its 5.125% Senior Notes due 2010 and 7.50% Senior ... conditions of the tender offer are described in the Offer ...
Cached Biology Technology:Pharmaceutical Institute Launches New E-Course Focused on Health Policy 2Pharmaceutical Institute Launches New E-Course Focused on Health Policy 3Quest Diagnostics Announces Final Tender Offer Results 2Quest Diagnostics Announces Final Tender Offer Results 3
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... tumors often fail to respond to promising new medication. ... tumor marker for the development of this resistance. A ... great the chances of success are for chemotherapy. At ... promising brain tumor therapy. Dr. Wolf Mller, senior ...
... first information about how fat causes hypertension have been identified ... identify which obese people and maybe some thin ones ... would work best for them. Medical College of ... PTP1B puts mice at risk for hypertension by interfering with ...
... introduced to the U.S. from Europe and other places, garlic ... new study indicates that eventually, however, its primary weapon ... potent. The study, in Proceedings of the National ... show that evolutionary forces can alter the very attributes that ...
Cached Biology News:Why don't brain tumors respond to medication? 2New information about how fat increases blood pressure could help identify those at risk 2New information about how fat increases blood pressure could help identify those at risk 3Over time, an invasive plant loses its toxic edge 2Over time, an invasive plant loses its toxic edge 3
Homo sapiens olfactomedin 1, transcript variant 3...
... agarose-digesting enzyme isolated from Pseudomonas atlantica. ... in agarose producing carbohydrate molecules that ... carbohydrate molecules will not interfere with ... Gelzyme enzyme can be used for ...
... the cellular components necessary for protein synthesis ... termination factors) but has not been treated ... primarily for the isolation of these components ... globin mRNA. Untreated Lysate is prepared from ...
...
Biology Products: